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Abstract
Background. Glioblastoma (GBM) is the most common primary malignant brain tumor in adulthood. Despite 
multimodality treatments, including maximal safe resection followed by irradiation and chemotherapy, the median 
overall survival times range from 14 to 16 months. However, a small subset of GBM patients live beyond 5 years 
and are thus considered long-term survivors.
Methods. A retrospective analysis of the clinical, radiographic, and molecular features of patients with newly 
diagnosed primary GBM who underwent treatment at The University of Texas MD Anderson Cancer Center was 
conducted. Eighty patients had sufficient quantity and quality of tissue available for next-generation sequencing 
and immunohistochemical analysis. Factors associated with survival time were identified using proportional odds 
ordinal regression. We constructed a survival-predictive nomogram using a forward stepwise model that we sub-
sequently validated using The Cancer Genome Atlas.
Results. Univariate analysis revealed 3 pivotal genetic alterations associated with GBM survival: both high tumor 
mutational burden (P = .0055) and PTEN mutations (P = .0235) negatively impacted survival, whereas IDH1 muta-
tions positively impacted survival (P < .0001). Clinical factors significantly associated with GBM survival included 
age (P < .0001), preoperative Karnofsky Performance Scale score (P = .0001), sex (P = .0164), and clinical trial par-
ticipation (P < .0001). Higher preoperative T1-enhancing volume (P = .0497) was associated with shorter survival. 
The ratio of TI-enhancing to nonenhancing disease (T1/T2 ratio) also significantly impacted survival (P = .0022).
Conclusions. Our newly devised long-term survival-predictive nomogram based on clinical and genomic data 
can be used to advise patients regarding their potential outcomes and account for confounding factors in 
nonrandomized clinical trials.
A validated integrated clinical and molecular 
glioblastoma long-term survival-predictive nomogram
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Key Points
•  Our new long-term survival-predictive nomogram can advise GBM patients on 
outcomes.
•  The nomogram may help account for factors confounding nonrandomized clinical 
trials.
The current standard-of-care for treatment of glioblastoma 
(GBM) is maximal safe resection followed by concurrent 
chemoradiation and cyclic administration of temozolomide. 
Despite aggressive, multimodality therapy, the median sur-
vival times range from 14 to 16 months.1,2 However, a small 
percentage of GBM patients (<3%) live well beyond 5 years, 
suggesting that these long-term survivors have a disease 
course that is inherently different from that in most GBM pa-
tients.3 The factors that define this subset of GBM patients 
who defy the odds remain largely unknown. Several small 
series have focused on clinical predictors of outcome,4,5 
whereas others have focused on molecular determinants of 
survival.6–8 Currently available calculators of predictive out-
comes in GBM patients are mostly reliant on clinical features 
(https://www.eortc.be/tools/gbmcalculator/; http://cancer4.
case.edu/rCalculator/rCalculator.html). An integrated clinical 
and molecular framework for long-term survival (LTS) has yet 
to be devised. To that end, the objective of the present study 
was to perform an in-depth analysis of a cohort of GBM pa-
tients to determine not only the clinical factors but also the 
molecular determinants of survival. As a result, we developed 
a survival-predictive nomogram to identify confounders that 
may be relevant for the assessment of nonrandomized GBM 
clinical trials and to enable oncologists to more appropriately 
advise patients regarding their potential outcomes.
Methods
Study Population
This study was conducted under The University of Texas 
MD Anderson Cancer Center Institutional Review Board-
approved protocol PA15-0636 and consisted of 80 patients 
with newly diagnosed GBM who underwent treatment at 
MD Anderson from November 1, 1996 to December 31, 2015 
and had sufficient quality and quantity of tissue available 
for next-generation sequencing and immunohistochemical 
analysis along with full radiographic and clinical annota-
tion. This study strictly excluded secondary IDH-mutant 
GBM with a multi-year prior history of known low-grade 
astrocytoma and was focused on de novo, classic spon-
taneously arising GBM. Patients were stratified into 3 
analysis groups: short-term survival (STS; <6  months 
[n  =  37]), median survival (MTS; ~15  months [n  =  22]), 
and LTS (>5 years [n = 21]). Four of the patients in the STS 
group and 3 of those in the MTS group were censored 
because they were lost to follow-up (ie, their exact dates 
of death were unavailable). Tumor diagnosis was made 
using magnetic resonance (MR) imaging and/or contrast-
enhanced computed tomography. All of the patients’ ini-
tial craniotomies for tumor resection were performed at 
MD Anderson. Histological diagnosis in each case was 
based on the World Health Organization Classification 
and determined by a board-certified pathologist. The pa-
tients’ demographic, clinical, and radiographic data were 
reviewed. Clinical variables included age at surgery, sex, 
and Karnofsky Performance Scale (KPS) score. Volumetric 
analysis was performed on immediate preoperative MR 
imaging. Preoperative and postoperative tumor volumes 
measured using MR imaging were quantified prospec-
tively using Vitrea (version 2) or MedVision (version 1.41) 
software. These software programs allow for calculation of 
the tumor area as outlined on selected axial or coronal im-
ages followed by estimation of the tumor volume based on 
the known thickness of the slice. Tumor contrast-enhanced 
volume was defined as the area of increased signal in-
tensity on contrast-enhancing T1-weighted MR images. 
Extent of resection (EOR) was calculated based on the pre-
operative and postoperative tumor volumes. A subset of 
Importance of the Study
Glioblastoma (GBM) survival is approximately a 
year. A small subset of GBM patients is afforded 
long-term survival but the features that predict 
this outcome are not fully delineated. This study 
integrates clinical, radiographic, and genomic 
data to assess the probability of long-term sur-
vival. We performed extensive molecular pro-
filing on a cohort of patients with de novo GBM 
and integrated this data with clinical and radio-
graphic features. We then constructed an inte-
grated predictive outcome nomogram based on 
age, Karnofsky Performance Scale score, and the 
mutational status of IDH1, PTEN, and TP53 which 
was validated with The Cancer Genome Atlas. 
This long-term survival-predictive score can pro-
vide clinicians with a framework to inform pa-
tients about their relative chances of long-term 
survival. The nomogram will also be a valuable 
assessment tool for clinical trial investigators, 
regulatory agencies, and other stakeholders to 
identify confounding variables influencing the 
interpretation of outcomes data.











patients had initial diagnostic biopsies at outside institu-
tions followed by definitive resection at MD Anderson. All 
“second-look” surgeries were performed within 6 weeks of 
biopsy confirming the tumor to be GBM.
Immunohistochemical Analysis
Immunohistochemical analysis was performed using en-
tire sections of formalin-fixed, paraffin-embedded GBM 
samples with automated staining techniques as we de-
scribed previously.9 Dilutions and conditions were per-
formed according to package insert instructions; they 
were optimized and validated and met the standards and 
requirements of the Clinical Laboratory Improvement 
Amendments, College of American Pathologists, 
and International Organization for Standardization. 
Immunohistochemistry results were evaluated independ-
ently by 6 board-certified neuropathologists. The primary 
anti-programmed death-ligand 1 (PD-L1) antibody SP142 
(Spring Bioscience) was used for detection. The chromo-
genic reporter 3, 3′-diaminobenzidine was used to facili-
tate colorimetric visualization of the antibody, yielding a 
brown stain that could be analyzed under a light micro-
scope. For an SP142 clone, the Rabbit LINKER visualiza-
tion system (Dako) was used. The staining was regarded 
as positive if its intensity on the membranes of tumor 
cells was greater than 1+ on a semiquantitative scale of 
0–3+ (0 for no staining, 1+ for weak cytoplasmic staining, 
2+ for moderate membranous staining, and 3+ for strong 
membranous staining) and the percentage of positively 
stained cells was greater than 5%. During the validation 
process for each analysis using immunohistochemistry, 
any interpathologist variability in evaluation was ad-
dressed in a microscopic examination session by all 6 
pathologists led by the medical director.
Next-Generation Sequencing Methods
Next-generation sequencing was performed with ge-
nomic DNA isolated from formalin-fixed, paraffin-
embedded tumor samples on the Illumina NextSeq 
platform. A  custom-designed SureSelect XT assay 
(Agilent Technologies) was used to enrich 592 whole-
gene targets (http://www.carislifesciences.com). Genetic 
variants were detected with greater than 99% confidence 
interval based on allele frequency and amplicon cov-
erage, with an average sequencing depth of coverage 
greater than 500× and analytic sensitivity of 5% var-
iant frequency. Variants were classified according to the 
American College of Medical Genetics and Genomics 
guidelines.10 Pathogenic variants, defined as known 
pathogenic mutations that promote tumorigenesis, 
presumed pathogenic variants (not germline with evi-
dence of pathogenicity in functional assays), or variants 
that were not wild type but could be associated with 
protein changes, were selected for analysis of their as-
sociation with survival. Wild type and benign variants 
that occur during somatic development and are not ca-
pable of causing disease were not included. Tumor mu-
tational burden (TMB) was calculated by counting all 
nonsynonymous missense mutations not previously 
reported as germline alterations. Specifically, TMB was 
calculated using somatic nonsynonymous missense 
mutations in accordance with the TMB Harmonization 
Project (Friends of Cancer Research; http://www.focr.
org/tmb), adding nonsynonymous, nonsense, in-frame 
indel, and frameshift variants after filtering out pre-
sumed germline variants determined from the Genome 
Aggregation Database (release 2.1; https://gnomad.
broadinstitute.org/), the Database of Single Nucleotide 
Polymorphisms (human build 151; https://www.ncbi.
nlm.nih.gov/snp/), and the Caris Life Sciences in-house 
benign database. About 1.4  Mb per tumor sample was 
sequenced.11
Statistical Methods
Univariate analysis to assess the associations of individual 
features with STS, MTS, and LTS was performed using an 
ordinal proportional odds regression model. Confidence 
intervals (CIs) were computed using Wald statistics and 
P values were determined using likelihood ratio tests. 
Features with P values of up to .10 in the univariate anal-
ysis were subjected to multivariate analysis. To select the 
best features for the model, the forward stepwise selec-
tion was used with the Akaike information criterion (AIC). 
AIC balances how well a model explains the data (quality 
of predictions) with the model’s complexity (number of 
features). The goal is to have a model that explains data 
well but is not too complex. Lower AIC values are better. 
Forward stepwise selection starts by constructing p 
single-feature models in which p is the number of fea-
tures under consideration. The best-fitting single-feature 
model, as measured by AIC, is chosen for step 2. In step 2, 
p−1 two-feature models are built. Each model uses the 
single best feature from the first step of the algorithm and 
one of the remaining p−1 features. The 2 features used in 
the best model are then selected for step 3. This process 
continues until all features are used or the AIC begins to 
increase (suggesting an excessively complex model). The 
results of the forward stepwise selection are shown in 
Supplementary Figure 1.
To address the differing prevalence of STS, MTS, and LTS 
in the MD Anderson cohort and GBM patient data in The 
Cancer Genome Atlas (TCGA), Bayes’ theorem was used. 
Let πm and πt be the known class prevalence for the MD 
Anderson and TCGA patients, respectively. Also, let f (x|c) 
be the probability of observing features x  given class c , 









were performed. Our strategy was to use the known 
πm(c|x) and πm(c) to determine f (x|c) from using the first 
equation. f (x|c) was then put into the second equation 
(along with πt(c), which is known) to determine πt(c|x). Of 
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note, f (x|c) can only be determined up to a multiplicative 
constant.
At fixed x , we seek sought the vector 
f = f (x|c) = ( f (x|STS), f (x|MTS), f (x|LTS)), which 
minimizes









We found f  at each vector of probabilities in the grid using 
a Newton-type algorithm.
Statistical analyses were performed using R statistical 
software (version 3.5.1) with packages survival v3.1–8, 
MASS 7.3–51.1, and plotted using gplot v2_3.2.1.
Results
Characteristics of the Patient Cohort
The median age of the MD Anderson GBM patient cohort 
was 57 years (range, 25–81 years), their median preoper-
ative KPS score was 90 (range, 40–100), and 63% (n = 50) 
of them were male (Table  1). Preoperative imaging re-
vealed that tumor necrosis predominated in the ana-
lyzed cohort, which is consistent with the radiographic 
features of GBM. We performed volumetric analysis on 
the T1 contrast-enhancing portion of the tumor, its T2/
fluid-attenuated inversion recovery (FLAIR) volume and 
its MRI tumor necrosis characteristics. No volumetric 
data were available for one patient. The median preoper-
ative T1 contrast-enhancing disease volume was 32.1 cm3 
(range, 0.4–111.0  cm3), and the median T2/FLAIR volume 
was 79.5 cm3 (range, 4.9–300.8 cm3). Five tumors did not 
show sufficient enhancement on T1-weighted sequences to 
be volumetrically measured, and 4 had no measurable T2 
volumes. For all other patients (n = 71), we calculated the 
ratio of contrast-enhancing to nonenhancing disease (T1/
T2 ratio), finding a median value of 41%. Tumor necrosis 
was present in 55 cases (69%), with a median volume of 
10.6 cm3 (range, 0.2–75.5 cm3). Three patients underwent 
biopsy only, with the remaining 77 undergoing resection. 
Of these patients, 74% (n = 57) has a gross total resection 
(≥97% resection of T1 contrast-enhancing disease), and 
66% (n = 51) had 100% resection of T1 contrast-enhancing 
disease. Three patients had diagnostic biopsies at outside 
institutions and subsequently presented to MD Anderson 
and underwent resection; we included these patients in 
the survival analysis. The overall median EOR was 100.0% 
(range, 50.5–100.0%) for T1 contrast-enhancing disease 
and 63.1% (range, 14.4–100.0%) for T2/FLAIR disease. 
Postoperatively, T2/FLAIR disease in one patient could not 
be assessed due to a large area of postoperative ischemic 
change that was indistinguishable from residual T2/FLAIR 
disease.
Clinical Factors Associated With Survival of GBM 
Patients
The median overall survival time in the cohort was 1.2 years, 
with 37 (46%) experiencing STS, 22 (28%) experiencing MTS, 
and 21 (26%) experiencing LTS. Consistent with reports in the 
literature,5,6 univariate analysis demonstrated that age was a 
significant predictor of overall survival (P < .0001; odds ratio 
[OR], 0.88 [95% CI, 0.84–0.92]; Table 2). Overall survival dur-
ations were shorter in male than in female patients (P = .0164; 
OR, 0.34 [95% CI, 0.14–0.85]). Additionally, patients with 
higher preoperative KPS scores had longer survival than 
did patients with lower scores (P < .0001; OR, 1.09 [95% CI, 
1.04–1.14]). Clinical trial enrollment at any point in the pa-
tients’ treatment course impacted the outcome, with trial par-
ticipants having a longer survival (P < .0001; OR, 6.52 [95% CI, 
2.51–16.92]). Multivariant analysis showed that higher KPS 
was significantly associated with clinical trial participation 
(P = .0143). Clinical trial participation was not significantly as-
sociated with IDH1 status (P = .3271).
The T1/T2 Ratio Impacts GBM Patient Survival
From a radiographic perspective, a higher preoperative T1 
contrast-enhancing tumor volume (P = .0497; OR, 0.98 [95% 
CI, 0.97–1.00]) was associated with a shorter survival time. 
More specifically, the T1/T2 ratio correlated negatively with 
survival. Patients with larger T1/T2 ratios (sample patient—
Figure  1) had a significantly shorter survival (P  =  .0022; 
OR, 0.08 [95% CI, 0.01–0.45]). Among the patients who 
experienced LTS (n = 21), volumetric data were available 
for 17, and of those, 15 (88%) had 100% resection of the 
T1-enhancing component of the tumor (median, 100.0% 
[range, 57.9–100.0%]). Volumetric data were available for 
all short-term survivors (n = 37), with 21 (57%) undergoing 
100% resection (24 patients had ≥97% resection).
  
Table 1. Clinical Characteristics of the GBM Patient Cohort (N = 80)
Characteristic n %
Sex   
 Female 30 38
 Male 50 62
Clinical trial enrollment   
 No 54 68
 Yes 25 31
 Unknown 1 1
Tumor necrosis (n = 77)   
 No 22 29
 Yes 55 71
Surgical approach   
 Craniotomy/resection 77 96
 Biopsy 3 4
EOR (n = 77)   
 GTR 57 74
 STR 20 26
EOR, extent of resection; GTR, gross total resection; STR, subtotal 
resection.
  











Genetic Determinants of GBM Patient Survival
Univariate analysis revealed that 2 gene mutations were sig-
nificantly associated with survival (Table  3). IDH1 mutations 
had the biggest impact on survival, with patients having 
IDH1-mutant tumors (n = 14) surviving longer than did those 
having IDH1–wild-type tumors (P < .0001; OR, 97.8 [95% CI, 
10.79–886.91]). Most of the long-term survivors (13 of 21) had 
this mutation, whereas none of the short-term survivors had it. 
PTEN status also influenced survival, with patients having tu-
mors with mutations of the PTEN genes experiencing shorter 
survival than did those with PTEN–wild-type tumors (P = .0235; 
OR, 0.23 [95% CI, 0.06–0.94]). None of the IDH1-mutated pa-
tients (n = 14) had PTEN mutations (n = 11). However, the corre-
lation was not statistically significant. PD-L1 expression was not 
associated with survival in our cohort.
Consolidating the overall mutational landscape, we 
evaluated the association of TMB with survival and found 
that a high TMB negatively impacted survival (P =  .0055; 
OR, 0.73 [95% CI, 0.58–0.94]). IDH1 mutation was signifi-
cantly associated with lower TMB (P = .0003). Furthermore, 
O[6]-methylguanine-DNA methyltransferase (MGMT) 
methylation was associated with LTS (P = .0032; OR, 3.94 
[95% CI, 1.52–10.22]).
Construction of the Predictive Nomogram
The dataset was missing the following variables for 
some patients: PD-L1 expression (n = 28), MGMT meth-
ylation status (n  =  10), T1/T2 ratio (n  =  9), volumetric 
EOR of enhancing disease (n = 7), volumetric EOR of T2/
FLAIR disease (n = 7), TMB (n = 6), T1-enhancing volume 
(n = 5), EOR of enhancing disease (n = 4), T2 volume in-
cluding T1 (n  =  4), necrosis volume (n  =  3), KPS score 
(n = 2), and clinical trial participation (n = 1). For PD-L1 
tumor staining and TMB analysis, these assays were be-
coming available as a Clinical Laboratory Improvement 
Amendments approved assay during data acquisition. 
The remaining missing variables were mostly related to 
the inability to precisely measure multifocal and com-
plex images. Genomic variables were coded as unfavor-
able if they were considered pathogenic or presumed 
pathogenic based on the American College of Medical 
Genetics and Genomics guidelines.10 We coded all other 
genetic alterations, such as benign, variant not detected, 
and variant of unknown significance, as neutral. Thus all 
genomic variables were binary. We then correlated each 
variable with STS, MTS, and LTS and ranked based on 
the significance of each correlation. We considered all 
  
Table 2. Univariate Analysis of the Study Patients (N = 80): Clinical and Radiographic Factors
Feature n OR 95% CI P
Age — 0.8797417 0.84–0.92 <.0001
Sex     
 Female 30 — — .0164
 Male 50 0.3437707 0.14–0.85  
KPS score — 1.0853484 1.04–1.14 <.0001
T1-enhancing volume — 0.9839941 0.97–1.00 .0497
T2 volume including T1 — 1.0027202 1.00–1.01 .4802
T1/T2 volumetric ratio — 0.0807405 0.01–0.45 .0022
Necrosis volume — 0.9699149 0.93–1.01 .0817
Volumetric EOR based on enhancement — 1.0087027 0.96–1.06 .7141
Volumetric EOR based on T2/FLAIR disease — 0.9947252 0.98–1.01 .5930
EOR based on enhancing disease     
 GTR 57 — — .3419
 STR 16 0.4584197 0.15–1.40  
 Biopsy 3 0.5608276 0.04–7.37  
PD-L1 status     
 Negative 46 — — .7869
 Positive 6 0.7866907 0.13–4.75  
TMB — 0.7378053 0.58–0.94 .0055
Clinical trial enrollment —    
 No 54 — — <.0001
 Yes 25 6.5197993 2.51–16.92  
MGMT methylation     
 No 38 — — .0032
 Yes 32 3.9444285 1.52–10.22  
KPS, Karnofsky Performance Scale; EOR, extent of resection; GTR, gross total resection; STR, subtotal resection; TMB, tumor mutational burden.
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variables with P values less than .1 in the univariate anal-
ysis to be potentially interesting.
We found that clinical trial enrollment correlated with 
survival. However, we eliminated this feature from the 
survival-predictive nomogram because clinical trial partici-
pation cannot be determined at the time of GBM diagnosis. 
We also removed TMB from our survival-predictive nom-
ogram because its definition varies from assay to assay, 
making reproduction with an independent dataset such as 
those in the TCGA difficult.
Model Building
We used a proportional odds ordinal logistic regression 
model to predict STS, MTS, and LTS probability given ac-
cording to patient features (covariates).12 We used forward 
stepwise selection with the AIC to select the best features 
for the model implemented using the MASS package in R 
statistical software.13 We used age, IDH1, KPS score, PTEN, 
and TP53 mutation status in the final model. The genomic 
variables IDH1, PTEN, and TP53 are all binary (either mu-
tated or not mutated). Supplementary Figure 1 shows that 
the model assigned low probability of LTS to the patients 
who actually experienced STS (concentration of red region 
near 0) and high probability of LTS to patients who actually 
experienced LTS (blue region mode near 1). The code used 
for building the model can be found at https://github.com/
longjp/GBMpredict. Statistical details of the proportional 
odds model, AIC, and forward stepwise selection are de-
scribed above.
Evaluation and Validation of the Survival-
Predictive Nomogram
We externally validated the model using GBM patient 
data from TCGA (n  =  592) with the following patient/sur-
vival proportions: STS (0–1  year), 0.42; MTS (1–5  years), 
0.52; and LTS (5+ years), 0.06. These proportions differed 
markedly from the proportions in our cohort, in which pa-
tients with LTS were deliberately oversampled to obtain 
enough patients to build a robust model (STS, 0.46; MTS, 
0.28; LTS, 0.26). To account for these differences in survival 
prevalence, we adjusted our probabilistic predictions to 
reflect the prevalence in TCGA using Bayes’ theorem as 
described above.
We then applied the model to the TCGA cohort and made 
probabilistic predictions for each patient. For any given 
value of age, KPS score, IDH1, PTEN, and TP53 mutation 
status, we obtained a set of 3 probabilities corresponding 
to the likelihood of STS, MTS, and LTS. Since 95 patients in 
the TCGA cohort are censored (patients are STS or MTS but 
alive at the time of the last follow-up so true survival is at 
least STS or MTS), we use the concordance index to assess 
the quality of these predictions.12 The C-index is the pro-
portion of comparable pairs of samples where the model 
predictions agree with the actual outcomes. A C-index of 
0.5 corresponds to a useless model (random guessing) 
and 1.0 to a perfect model. Our model achieves a C-index 
of 0.66 on the independent TCGA cohort (P < .00001). The 
finalized embargoed nomogram can be found at https://bi-
ostatistics.mdanderson.org/shinyapps/GBM_Predict/ (us-
ername: GBM; password: predict; Figure 2).
  
T1 vol. T2/FLAIR vol.
Figure 1. Representative MR images of a newly diagnosed GBM patient at presentation demonstrating a T1 gadolinium contrast-enhancing 
volume of 14.2 cm3 (left) and T2/FLAIR volume of 104.4 cm3 (right). In this patient, the T1/T2 ratio was 0.13.
  












Long-term survival in patients with GBM is uncommon, 
and survival for at least 5  years is quite rare. In this re-
port, we describe clinical, radiographic, and molecular 
features associated with LTS in this patient population. 
These key features should be accounted for during clin-
ical trial interpretation as confounders when assessing 
outcomes in GBM patients. Notably, 50% of the long-term 
survivors in our study participated in at least one clinical 
trial. This may explain why the initial results of many un-
controlled single-institution GBM studies appear to be 
promising but the effect is diminished once the studies 
are expanded to multi-institutional controlled trials. 
Researchers have shown that clinical features such as 
young age and a good KPS score at the time of diagnosis 
are favorable prognostic factors in GBM patients.14–16 
Because long-term survivors represent only a small subset 
of GBM patients, their clinical characteristics were only 
minimally addressed in earlier studies, often with limited 
sample sizes and follow-up durations.17–21 In one study, 
investigators evaluated 55 patients with GBM who under-
went surgery and adjuvant radiotherapy and survived be-
yond 36 months.6 That study demonstrated that LTS was 
associated with high functional status and young age. 
Another retrospective analysis compared 16 long-term 
survivors who survived for more than 2 years with short- 
and medium-term survivors and found that KPS score at 
diagnosis, age, initial tumor resection (as opposed to bi-
opsy), chemoradiation, and early progression were factors 
associated with survival in these groups.17 However, few 
studies22 account for radiographic, clinical, and molec-
ular determinants of the outcome as in the present study. 
Although researchers have attempted to correlate features 
of advanced imaging modalities such as radiomic and 
  
Table 3. Univariate Analysis of the Study Patients (N = 80): Molecular Variables
Variable {“Gene?”} Mutationa n OR 95% CI P
APC 0 79 — —  
 1 1 — —  
BRAF 0 78 — — .6671
 1 2 1.5837893 0.19–13.36  
CDKN2A 0 79 — —  
 1 1 — —  
EGFR 0 67 — — .3197
 1 13 0.5516976 0.16–1.86  
FBXW7 0 79 — —  
 1 1 — —  
FGFR3 0 79 — —  
 1 1 — —  
IDH1 0 66 — — <.0001
 1 14 97.8096211 10.79–886.91  
KRAS 0 79 — —  
 1 1 — —  
MUTYH 0 78 — — .6769
 1 2 0.5930654 0.05–7.64  
NF1 0 75 — — .3161
 1 5 0.4264895 0.07–2.50  
PIK3CA 0 73 — — .4826
 1 7 1.6332647 0.41–6.59  
PTEN 0 69 — — .0235
 1 11 0.2313771 0.06–0.94  
PTPN11 0 79 — —  
 1 1 — —  
SUFU 0 79 — —  
 1 1 — —  
TP53 0 57 — — .0622
 1 23 2.4522865 0.93–6.45  
a0, no mutation; 1, mutation.
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textural MR imaging features with GBM outcome,23–25 the 
present study shows the utility of conventional standard 
MR imaging in assessing the outcome of GBM. An ad-
vantage of the nomogram is the ease of interrogation of 
outcome in the clinical domain relative to more complex 
mathematical modeling even if the latter is more accu-
rate.26 Furthermore, our analysis demonstrated that the 
influence of a pathogenic mutation of IDH1, which is di-
rectly associated with age, surpassed that of many other 
previously documented factors. One could argue that the 
presence of an IDH1 mutation may demonstrate that these 
cases are not classical GBM. There is a growing consensus 
that IDH-mutant astrocytomas and IDH-wildtype, grade 4 
diffuse astrocytomas are 2 biologically distinct tumors.27,28 
Notably, board-certified neuropathologists who advise re-
garding the World Health Organization criterion reviewed 
all of the cases, none of the analyzed cases were sec-
ondary GBM, and IDH1 mutations were present in about 
5% of cases in a previous study.29
Because the median EOR in our study cohort was 
100%, an excellent resection is a baseline criterion for 
subsequent application of the survival-predictive nom-
ogram. In a recently published GBM nomogram, in ad-
dition to age, KPS, and gender, unlike the current study, 
these authors included EOR to their internally validated 
nomogram.30 Gorlia et  al.31 published a large study 
compiling data from 573 GBM patients to construct a 
predictive nomogram for 2-year survival with a focus 
on the impact of MGMT status. However, at that time no 
validation set was available and our current study has 
a greater depth of molecular profiling. Genetic analysis 
provided the compelling perspective that the presence 
of a pathogenic IDH1 mutation is one of the strongest 
influences on LTS in GBM patients. To account for the 
possibility of inclusion of patients with secondary GBM 
in our LTS cohort, we performed genetic analysis of the 
long-term survivors that demonstrated all of their tu-
mors had intact ATRX and that none of them had previ-
ously documented gliomas, indicating that these were 
de novo GBMs. None of the IDH-mutant tumors showed 
the classic molecular alteration triad of IDH mutation, 
TP53 mutation, and ATRX mutation, which represents 
a rare subtype. Among prior profiling of IDH mutants 
that are non-co-deleted, approximately 95% are TP53 
and 75% are ATRX mutant.32,33 We validated the GBM 
survival-predictive nomogram using GBM patient data 
in TCGA because validation in other large cases series 
was not possible, as outcome data were only reported 
for up to 3  years, the numbers of 5-year survivors 
lacked sufficient statistical power, and/or genomic data 
were insufficient.5,34–37 In the future, more molecular 
information on patient GBMs will be available both 
because it is a requirement for diagnosis using World 
Health Organization criteria and because genetic pro-
filing is becoming more mainstream. Therefore, we will 
update the nomogram in the future to enhance its accu-
racy in survival prediction.
There are some study limitations that warrant discus-
sion. The nomogram was developed based on the data 
from an academic institution, and although validated with 
TCGA, may not be reflective of patients treated in a general 
community practice setting. Biases such as the overall sur-
gical EOR from the academic group was notably high and 
may not be recapitulated without neuro-oncology neuro-
surgical expertise. Despite the extensive tumor profiling 
performed, the patient cohort itself is not large relative 
to more common cancers. Additionally, epigenetic pro-
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Figure 2. The application for GBM survival prediction using the survival-predictive nomogram. A representative clinical example is shown in 
which a 43-year-old GBM patient with a KPS score of 70 had an IDH1-mutant tumor. This patient had a 2%, 72%, and 26% chance of being a short-
term survivor (<6 months), long-term survivor (>5 years), and median-term survivor (~15 months), respectively. Two percent of patients had this 
outcome.
  











nomogram but this is not routinely performed on clinical 
specimens at this time.
In summary, this study demonstrated a validated integra-
tion of clinical, radiographic, and genomic data to predict the 
survival of GBM. Note, our C-index of 0.66 compares favor-
ably with 2 other published GBM nomograms (0.65730 and 
0.69538). A C-index of 0.66 indicates additional opportunities 
to improve the predictive capabilities of this nomogram likely 
based on epigenetic profiling, but they have yet to be used 
for clinical profiling in GBM patients. Although prognoses for 
GBM remain poor overall, this study does provide optimism 
for a subgroup of patients. Our new LTS-predictive score 
can provide clinicians with an easier way to inform patients 
about their relative chances of LTS. These findings may also 
assist clinical trial investigators as well as regulatory agen-
cies and other stakeholders in identifying confounding vari-
ables influencing the interpretation of GBM outcome data in 
nonrandomized clinical trials.
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